The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA

Annals of Clinical Biochemistry

Volumn 35, Issue 1, 1998, Pages 99-103

  Maestranzi, S ^a   Przemioslo, R ^a   Mitchell, H ^b   Sherwood, R A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Colonic cancer; Pancreatic cancer

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; TUMOR MARKER;

ALBUMIN BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BLOOD LEVEL; CHOLESTASIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EPITHELIUM CELL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

HEPATITIS C VIRUS;

EID: 0031982932     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329803500113     Document Type: Article

References (14)

1. Haglund C, Lundin J, Kuusela P, Roberts PJ. CA242, a new tumour marker for pancreatic cancer: A comparison with CA19-9, CA50 and CEA. Br J Cancer 1994; 70: 487-92
2. Sperti C, Pasquali C, Catalani S, Cappellazzo F, Bonadimani B, Behboo R, et al. CA19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 1993; 52: 137-41
3. Basso D, Meggiato T, Fabris C, Plebani M, Forgar P, Panozzo MP, et al. Extra-hepatic cholestasis determines a reversible increase of glycoprotein tumour markers in benign and malignant disease. Eur J Clin Invest 1992; 22: 800-4
4. Benamouzig R, Buffett C, Fourre C, Ink O, Moati F, Etienne JP. Serum levels of carbohydrate antigen determinant (CA19-9) in obstructive jaundice. Dig Dis Sci 1989; 34: 1640-2
5. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci 1988; 33: 1223-5
6. Harmenberg U, Wahren B, Wiechel K-L. Tumor markers carbohydrate antigen CA19-9 and CA-50 and CEA in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988; 48: 1985-8
7. Collazos J, Genolla J, Ruibal A. CA19-9 in non-neoplastic liver disease: A clinical and laboratory study. Clin Chim Acta 1992; 210: 145-51
8. Pearce S, Thornes H, Carr D, Tanner A. Diagnostic pitfall; interpretation of CA19-9 concentrations in the presence of hepatic dysfunction. Gut 1994; 35: 707-8
9. Collazos J, Genolla J, Ruibal A. CA125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. Scand J Clin Lab Invest 1992; 52: 201-6
10. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bouhon C. Elevation of CA125 in patients with benign and malignant ascites. Cancer 1987; 59: 213-7
11. Eerdekens MW, Nouwen EJ, Pollet DE, Briers TW, De Broe ME. Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant disease. Clin Chem 1985; 31: 687-90
12. Haga Y, Sakamoto K, Egami H, Yoshimura R, Mori K, Akagi M. Clinical significance of serum CA125 values in patients with cancers of the digestive system. Am J Med Sci 1986; 292: 30-4
13. Bergmann JF, Beaugrand M, Labadie H, Bidant JM, Boubon C. CA125 (ovarian tumour-associated antigen) in ascitic liver diseases. Clin Chim Acta 1986; 155: 163-6
14. Ramage JK, Donaghy A, Farrant M, Iorns R, Williams R. Serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-9